Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy

Yoshihiko Maehara; Sho Nishimura; Hiroshi Saeki; Tomonori Nakanoko; Yuta Kasagi; Yasuo Tsuda; Yoko Zaitsu; Kouji Andou; Yuichiro Nakashima; Y. U. Imamura; Kippei Ohgaki; Eiji Oki; Ohga Saiji; Katsumasa Nakamura; Masaru Morita

Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy

Yoshihiko Maehara, Sho Nishimura, Hiroshi Saeki, Tomonori Nakanoko, Yuta Kasagi, Yasuo Tsuda, Yoko Zaitsu, Kouji Andou, Yuichiro Nakashima, Y. U. Imamura, Kippei Ohgaki, Eiji Oki, Ohga Saiji, Katsumasa Nakamura, Masaru Morita

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.

Original language	English
Pages (from-to)	2299-2304
Number of pages	6
Journal	Anticancer research
Volume	35
Issue number	4
Publication status	Published - Apr 1 2015

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Maehara, Y., Nishimura, S., Saeki, H., Nakanoko, T., Kasagi, Y., Tsuda, Y., Zaitsu, Y., Andou, K., Nakashima, Y., Imamura, Y. U., Ohgaki, K., Oki, E., Saiji, O., Nakamura, K., & Morita, M. (2015). Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy. Anticancer research, 35(4), 2299-2304.

@article{9513cc3d7b564bd287728e70d7fe1bb6,

title = "Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy",

abstract = "Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.",

author = "Yoshihiko Maehara and Sho Nishimura and Hiroshi Saeki and Tomonori Nakanoko and Yuta Kasagi and Yasuo Tsuda and Yoko Zaitsu and Kouji Andou and Yuichiro Nakashima and Imamura, {Y. U.} and Kippei Ohgaki and Eiji Oki and Ohga Saiji and Katsumasa Nakamura and Masaru Morita",

year = "2015",

month = apr,

day = "1",

language = "English",

volume = "35",

pages = "2299--2304",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "4",

}

TY - JOUR

T1 - Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy

AU - Maehara, Yoshihiko

AU - Nishimura, Sho

AU - Saeki, Hiroshi

AU - Nakanoko, Tomonori

AU - Kasagi, Yuta

AU - Tsuda, Yasuo

AU - Zaitsu, Yoko

AU - Andou, Kouji

AU - Nakashima, Yuichiro

AU - Imamura, Y. U.

AU - Ohgaki, Kippei

AU - Oki, Eiji

AU - Saiji, Ohga

AU - Nakamura, Katsumasa

AU - Morita, Masaru

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.

AB - Background/Aim: Definitive chemoradiotherapy (dCRT) is frequently administered in oesophageal cancer. We carried out hyperthermochemotherapy (HCT) for residual or recurrent cases after dCRT for oesophageal cancer. The aim of this study was to elucidate the usefulness of salvage HCT for these patients. Patients and Methods: Salvage HCT after dCRT was performed in 11 patients with residual or recurrent oesophageal cancer. We used an 8-MHz radiofrequency capacitive heating system for hyperthermia. The combined chemotherapy comprised of cisplatin/5-fluorouracil, an oral fluoropyrimidine and irinotecan. Results: There were no severe adverse events caused by hyperthermia. Complete response and stable disease was achieved in three and five patients, respectively; symptoms were improved in the remaining three patients. The median survival time after HCT was 12 (range=3-88) months. Conclusion: HCT is a feasible and potent salvage therapy for patients with residual or recurrent oesophageal cancer after dCRT, unless salvage surgery is indicated.

UR - http://www.scopus.com/inward/record.url?scp=84928402428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928402428&partnerID=8YFLogxK

M3 - Article

C2 - 25862892

AN - SCOPUS:84928402428

SN - 0250-7005

VL - 35

SP - 2299

EP - 2304

JO - Anticancer research

JF - Anticancer research

IS - 4

ER -

Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this